Drug Enforcement D-0237-2025

CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Status

Ongoing

Classification

Class II

Report Date

February 26, 2025

Termination Date

—

Product Information

Product description
Atomoxetine Capsules, USP, 100 mg, 30 capsule bottles, Rx Only, Manufactured for: Glenmark Pharmaceuticals Inc., NJ, USA, Product of India, NDC 68462-271-30.
Product quantity
39,168 bottles
Reason for recall
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
Recall initiation reason
—
Initial firm notification
Letter
Distribution pattern
Nationwide within the U.S

Location & Firm

Recalling firm
Glenmark Pharmaceuticals Inc., USA
Address
750 Corporate Dr, N/A

United States
Voluntary / Mandated
Voluntary: Firm initiated
Status date
—

Codes & Dates

Recall number
D-0237-2025
Event ID
96194
Recall initiation date
January 29, 2025
Center classification date
February 20, 2025
Code info
Lot Numbers: 19234955, 19234956, Exp.: 11/2025; 19240971, Exp.: 2/2026; 19241864, Exp.: 4/2026.
More code info
—